Pharmaceutical

FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s

The FDA has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat Parkinson’s disease (PD).

Jun 13, 2025 - 06:00
FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
The FDA has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat Parkinson’s disease (PD).
Read the original article

Tags:

Previous Article

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Next Article

SpliceBio secures $135m for gene therapy development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GEMMABio raises $34m to advance gene therapy programmes 

GEMMABio raises $34m to advance gene therapy programmes 

Dec 25, 2024

FDA rejects Lykos MDMA therapy, asks for another Phase III trial

FDA rejects Lykos MDMA therapy, asks for another Phase ...

Aug 13, 2024

CD70 CAR-T by UTC Therapeutics for Relapsed Chronic Lym...

Aug 10, 2023